Jafron Biomedical Co

Jafron Biomedical Co Operating Cash Flow

The Operating Cash Flow of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 721.22 M CNY. In the previous year, Operating Cash Flow was 1.05 B CNY — a change of -31.38% (lower).

Operating Cash Flow

721.22 MCNY

YoY

-31.38%

Last updated:

Operating Cash Flow of Jafron Biomedical Co is 2025 721.22 M CNY. Operating Cash Flow of Jafron Biomedical Co was 2024 1.05 B CNY. It decreases by -31.38% lower compared to the previous year.

The Jafron Biomedical Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
384.08 M CNY
Jan 1, 2019
583.50 M CNY
Jan 1, 2020
957.49 M CNY
Jan 1, 2021
1.25 B CNY
Jan 1, 2022
883.80 M CNY
Jan 1, 2023
916.74 M CNY
Jan 1, 2024
1.05 B CNY
Jan 1, 2025
721.22 M CNY
The Jafron Biomedical Co Operating Cash Flow history
YEAROperating Cash FlowYoY
721.22 MCNY-31.38%
1.05 BCNY+14.64%
916.74 MCNY+3.73%
883.80 MCNY-29.26%
1.25 BCNY+30.49%
957.49 MCNY+64.10%
583.50 MCNY+51.92%
384.08 MCNY+26.30%
304.10 MCNY+70.23%
178.64 MCNY-12.94%
205.18 MCNY+49.38%
137.35 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Operating Cash Flow of Jafron Biomedical Co is 721.22 M CNY in 2025.

Operating Cash Flow of Jafron Biomedical Co changed from 1.05 B CNY to 721.22 M CNY, representing a -31.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Jafron Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co